The stock price of Cardiol Therapeutics Inc (NASDAQ: CRDL) has jumped by 3.27 compared to previous close of 1.53. Despite this, the company has seen a gain of 1.28% in its stock price over the last five trading days. proactiveinvestors.com reported 2024-11-18 that Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) announced encouraging results from its Phase II MAvERIC-Pilot study, showcasing the sustained efficacy of its anti-inflammatory therapy, CardiolRx, in treating symptomatic recurrent pericarditis. The findings, which were presented at the American Heart Association Scientific Sessions 2024, highlighted marked improvements in pericarditis pain and inflammation, with benefits persisting throughout the 26-week trial.
Is It Worth Investing in Cardiol Therapeutics Inc (NASDAQ: CRDL) Right Now?
The stock has a 36-month beta value of 0.89. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CRDL is 77.27M, and at present, short sellers hold a 1.28% of that float. On November 28, 2024, the average trading volume of CRDL was 479.49K shares.
CRDL’s Market Performance
CRDL stock saw a decrease of 1.28% in the past week, with a monthly decline of -13.66% and a quarterly a decrease of -15.96%. The volatility ratio for the week is 6.83%, and the volatility levels for the last 30 days are 7.57% for Cardiol Therapeutics Inc (CRDL). The simple moving average for the last 20 days is -11.81% for CRDL’s stock, with a simple moving average of -19.69% for the last 200 days.
Analysts’ Opinion of CRDL
Many brokerage firms have already submitted their reports for CRDL stocks, with ROTH MKM repeating the rating for CRDL by listing it as a “Buy.” The predicted price for CRDL in the upcoming period, according to ROTH MKM is $10 based on the research report published on June 26, 2024 of the current year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see CRDL reach a price target of $9. The rating they have provided for CRDL stocks is “Buy” according to the report published on April 22nd, 2024.
CRDL Trading at -16.68% from the 50-Day Moving Average
After a stumble in the market that brought CRDL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -49.36% of loss for the given period.
Volatility was left at 7.57%, however, over the last 30 days, the volatility rate increased by 6.83%, as shares sank -13.19% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -28.18% lower at present.
During the last 5 trading sessions, CRDL rose by +1.28%, which changed the moving average for the period of 200-days by +54.90% in comparison to the 20-day moving average, which settled at $1.7915. In addition, Cardiol Therapeutics Inc saw 87.38% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for CRDL
The total capital return value is set at -2.29. Equity return is now at value -158.52, with -118.55 for asset returns.
Currently, EBITDA for the company is -29.59 million with net debt to EBITDA at 0.42. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.49.
Conclusion
To sum up, Cardiol Therapeutics Inc (CRDL) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
